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Abstract. The polypyrimidine tract binding protein
(PTB) is a 58-kDa RNA binding protein involved in
multiple aspects of mRNA metabolism including
splicing regulation, polyadenylation, 3’end formation,
internal ribosomal entry site-mediated translation,
RNA localization and stability. PTB contains four
RNA recognition motifs (RRMs) separated by three
linkers. In this review we summarize structural
information onPTB in solution that has been gathered
during the past 7 years using NMR spectroscopy and
small-angle X-ray scattering. The structures of all
RRMs of PTB in their free state and in complex with
short pyrimidine tracts, as well as a structural model of
PTB RRM2 in complex with a peptide, revealed
unusual structural features that provided new insights
into the mechanisms of action of PTB in the different
processes of RNA metabolism and in particular
splicing regulation.
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The many functions of polypyrimidine tract binding
protein
The polypyrimidine tract binding protein (PTB), also
referred to as hnRNP I, is an RNA binding protein of
58 kDa shown to be involved inmany different aspects
of RNAmetabolism and, as its name indicates, to bind
preferentially poly-pyrimidine stretches [1, 2].
The most intensively studied function of PTB is its
role as a regulator of alternative splicing (reviewed in
[3–5]). In alternative splicing regulation, PTB binds
to splicing silencer elements within the pre-mRNA
(Fig. 1) and has been shown to be responsible for
repression (i.e. , exclusion) of many tissue-specific
exons in vertebrates including its own mRNA [1, 4,
6–36]. PTB can repress different classes of alter-
native exons, namely cassette exons (Fig. 1a, d),
mutually exclusive exons (Fig. 1b) and alternative
3’terminal exons (Fig. 1c). The distribution of PTB
binding sites within introns has led to several
proposed models of PTB action. For example, PTB
could interfere with spliceosome assembly by bind-
ing to the branch point pyrimidine tract and there-
fore directly sequestering the branch-point or com-
peting with U2AF, an essential component of the
constitutive splicingmachinery [2, 15, 22, 32]. Inmost
cases, however, the exons silenced by PTB are flanked
by PTB binding sites on both adjacent introns, and
mutations of upstream PTB binding sequences have
been shown to reduce binding of PTB to the down-
stream sites [7]. Silencing of PTB-regulated exons was
hence postulated to be due to the creation of a zone of
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silencing across the exon, either by oligomerization of
PTB across the entire exon or by multimerization of
upstream and downstream PTB to introduce a loop in
theRNA [3].More recently, it was found that PTB can
act more indirectly, at early stages of spliceosome
assembly, by preventing the establishment of produc-
tive interactions between U2AF and the U1 snRNP.
This is mediated by PTB binding to intronic [11] or
exonic sequences [27] that prevent intron or exon
definition, respectively.
PTB is widely expressed across all developmental
stages and cell types, and often represses the splicing
of strictly tissue-specific exons outside of this partic-
ular tissue [5, 37]. Hence, mechanisms that release
PTB are important for tissue-specific regulation of
splicing.Another facet of splicing regulation byPTB is
the existence of co-repressors like Raver1 [38, 39].
Raver1 recruitment is essential for effective repressor
function of PTB in certain pre-mRNAs, for example
for the splicing repression of a-tropomyosin exon 3,
while in other systems PTB alone is sufficient.
Furthermore, tissue-specific paralogs of PTB exist,
such as neuronally enriched PTB [9, 40] (nPTB), the
smooth muscle-specific variant (smPTB) [41] or
ROD1 the variant found in rat hematopoietic cell
[42], which appear to have different effects on splicing
regulation [9, 41].
The second most studied function of PTB is its role in
internal ribosomal entry site (IRES)-mediated trans-
lation initiation of both cellular and viral mRNAs.
IRESs are large RNA structures present in the 5’-
untranslated regions (UTR) of some cellular mRNAs
[43, 44] and of many viral mRNAs [45] (Fig. 2). IRESs
help recruiting the translation machinery to initiate
translation. This recruitment often requires cellular
factors binding the IRES (initiation of translation
accessory factors, ITAFs) for efficient translation
initiation [43, 44, 46, 47]. PTB is one of the most
frequently encountered ITAFs and was found to be
implicated in IRES-mediated translation of several
Figure 1. Polypyrimidine tract binding protein (PTB) is a ubiquitous regulator of alternative splicing that influences different types of
alternative-splicing events (a) PTB represses theN1 “cassette-exon” in the c-src pre-mRNA[7, 9, 10, 103]. (b) PTB represses the “mutually
exclusive” SM exon of the a-actinin mRNA [12, 13]. (c) PTB regulates the choice of the 3’-terminal exon of the calcitonin/CGRPmRNA
[104]. (d) PTB autoregulates its own splicing and itsmRNA level by repressing the inclusion of its own exon 11. Skipping of exon 11 of PTB
mRNA leads to non-sense-mediated decay (NMD) [16]. Black boxes indicate the location of pyrimidine tracts bound by PTB. Intronic
sequences are shown in yellow, while colored boxes indicate exonic sequences. Arrows indicates splicing in the presence (+) or absence (–)
of PTB.
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human viruses including hepatitis viruses A and C
(although this is controversial [48, 49]) and several
picornavirus (aphtoviruses and cardioviruses, Fig. 2).
Several footprinting studies have mapped PTB bind-
ing sites on different IRESs and identified several
pyrimidine stretches embedded in stem loops and
single-stranded regions (in domain K and H of the
picornaviruses type II IRESs [50, 51], in domain 3 of
the hepatitis C virus [52] and also in cellular RNAs
[53–55], see Fig. 2). Moreover, reports have shown
that interactions between PTB (or the neuronal
nPTB) and cellular [56] or viral IRESs [51] are
essential for the IRESs to attain their correct func-
tional conformation. Hence, in its interaction with
IRES RNAs, PTB acts as an RNA chaperone.
Although in most cases PTB positively regulates
IRES-mediated translation of cellular RNA [55–59],
PTB can also be a negative regulator, like with the
IRES of the UNR protein (upstream of N-ras),
another ITAF [60], or of the bip mRNA [61]. More
recently, PTB was also found associated with the
3’UTR of the ATP synthase b-subunit, where it helps
enhancing translation in a cap-independent manner
[62].
In addition to its role in splicing and translation
regulation, PTB is implicated in 3’-end processing [63,
64], localization [65, 66], and stability [67–75] of
various cellular mRNAs. In these systems, PTB acts
through pyrimidine-tract binding sites within 5’ and/or
3’UTRs. Finally, recent genome-wide investigations
[76] have identified the association of PTB with a
distinct subset of cellular mRNAs that encode pro-
teins implicated in cellular transport, vesicle traffick-
ing and apoptosis [77], suggesting even more regu-
latory functions for PTB in the cell.
The structure of PTB in its free state
Human PTB has a molecular mass of about 58 kDa. It
consists of four RNA recognition motifs of the RRM/
RBD/RNP type (RNA recognition motif/RNA bind-
ing domain/ribonucleoprotein) that are connected by
linkers, plus an N-terminal nuclear localization signal
(NLS) sequence (Fig. 3a). RRMs typically have a size
of about 90 amino acid residues that fold in a babbab
topology, where a four-stranded b-sheet packs against
the two a-helices [78]. In terms of primary sequence,
RRMs are characterized by two conserved amino acid
stretches termed RNP2 ([I/L/V]-[F/Y]-[I/L/V]-X-N-
L) and RNP1 ([R/K]-G-[F/Y]-[G/A]-[F/Y]-[I/L/V]-
X-[F/Y]). Interestingly, although theRRMdomains of
PTB could be identified in sequence homology
searches, they match very poorly to this consensus
(Fig. 3a). In particular, they lack most of the aromatic
residues. In other RRM-containing proteins, however,
these aromatic side chains have been shown to be
crucial for both folding of the domain and RNA
recognition, as one of them makes up part of the
hydrophobic core of the domain, while others, in
Figure 2. PTB regulates internal ribosomal entry site (IRES)-mediated translation initiation of many viral and cellular mRNAs. The
secondary structures of two viral IRESs are shown: (a) FMDV (foot and mouse disease virus) [50] and (b) EMCV (encephalomyocarditis
virus) [50]. The secondary structures of three cellular IRESs are shown: (c) APAF-1 (apoptosis protease activating factor 1) [56], (d)
Artificial IRES [53] and (e) MTG8a [53]. Black lines indicate the locations of the pyrimidine tracts bound by PTB.
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particular the aromatics at position 2 of RNP2 and
positions 3 and 5 of RNP1, are commonly found to
make direct contacts to RNA bases. These aromatic
side chains are situated on the surface-exposed side of
the structurally central b1 and b3 strands and provide
a hydrophobic surface ideal for accommodating the
bases of single-stranded nucleic acid molecules [78].
The apparent absence of these critical features in the
primary sequence of PTB (Fig. 3a) has initially raised
the interest in atomic resolution structures of PTB
RRMs (Fig. 3b–e). The earliest of these studies
describes the nuclear magnetic resonance (NMR)
structure of a construct containingRRMs 3 and 4 [79].
This study revealed that despite the poor match with
the RNP consensus, both domains fold in the canon-
ical babbab RRM topology. In addition, quite un-
expectedly, RRM3 features a large structured C-
terminal extension that folds into an additional fifth b-
strand (Fig. 3e). This strand lies anti-parallel to b2 on
one side of the b-sheet and is connected to b4 on the
opposite side by a long loop that stretches across the
entire sheet. In this structure, which was solved in the
absence of an RNA target, this linker seems to be
fairly mobile and does not appear to make any
contacts with the rest of the domain. Heteronuclear
1H-15N NOE experiments confirmed that this linker
undergoes fast internal motion in the sub-nanosecond
time scale [79]. Both domains are characterized by a
densely packed hydrophobic core and a mutational
analysis shows that amino acids at those b-sheet
positions that are usually occupied by aromatic side
chains that stack with RNA bases, are important for
RNA binding in PTB RRMs 3 and 4 as well, despite
their non-aromatic nature [79]. Initially, RRM3 and 4
of PTB were suggested to be independent based on
the lack of interdomain NOEs between the domains
[79]. However, a subsequent structural characteriza-
tion of the same construct revealed that this was not
true [80]. In this second NMR study, segmental
isotope labeling of the two domains was employed
to obtain a large number of inter-domain distance
constraints and demonstrate unambiguously the ex-
tensive interdomain interaction [80] (Fig. 3f). Meas-
urements of protein dynamics, as well as a mutational
analysis, could further confirm the interaction. As
many as 20 side chains that lie in both helices of
RRM3, in helix 2 of RRM4 and in the interdomain
linker form a hydrophobic cluster that glues the two
domains together so that their RNA binding inter-
faces point in opposite directions [80]. This large
interaction between twoRRMs is very unusual among
RRMs in their free state, the only other example being
the recent structure of Prp24, a protein containing
three RRMs [81]. The amino acids contributing to the
unusual inter-domain interactions between RRM3
andRRM4 are highly conserved across species, as well
as in PTBparalogs [41, 42] like nPTB [9, 40] and hence
it seems likely that this topology is functionally
significant.
The NMR structures of free RRM1 and RRM2 have
been assessed in another study [82]. This analysis
revealed that RRM1 folds as a canonical babbab
RRM (Fig. 3b). Interestingly, the C terminus of this
domain binds across the b-sheet in a conformation
that is stabilized by numerous hydrophobic contacts,
suggesting that the b-sheet might be incapable of
binding RNA. Nevertheless, chemical shift mapping
experiments revealed that RRM1 uses the canonical
b-sheet binding surface for the recognition of RNA
ligands [82]. It remained unclear, however, whether a
conformational change, i.e. , the displacement of the C
terminus from the sheet, was necessary for RNA
binding. RRM2, on the other hand, has a tertiary
structure resembling RRM3, with the domain being
extended by a fifth b-strand (Fig. 3c). This additional
b-strand seems to be stabilized in both RRMs by a
stacking interaction between a tyrosine in b5 (Y275 in
RRM2 and Y430 in RRM3), and a histidine (H201 in
RRM2) or a phenylalanine (F365 in RRM3) from a-
helix1 (Fig. 3c, e). In the case of RRM2, however, the
b4-b5 linker is fairly short and rigid and makes close
contacts to the b-sheet. Chemical shift mapping of this
domain furthermore shows that the C-terminal ex-
tension and b5 both participate in RNA binding [82].
However, all NMR structures of PTB were solved
using either single domains or tandem domain con-
structs and it remained unclear how full-length PTB
behaves in solution. Are RRM1, RRM2 and RRM34
really fully independent, or is there a preferred
relative orientation of the domains? Small angle X-
ray scattering experiments with full-length PTB and
different PTB domain constructs provided low reso-
lution structures of the entire protein and hence
insight into these questions [82, 83]. These studies
confirmed that the RRM34 construct adopts a com-
pact, globular structure and revealed a more or less
linear arrangement of the four RRM domains, result-
ing in an elongated particle. Furthermore, it appears
that there is reduced conformational flexibility be-
tween RRMs 2 and 3; probably not caused by direct
contacts between the domains, but possibly due to
transiently structured elements within the inter-do-
main linker [83]. Interestingly, this linker is subject to
alternative splicing and hence its behavior in solution
is likely to be relevant for proper PTB function.
Finally, these studies, as well as others, could unam-
biguously show that full-length PTB is a monomer in
solution [10, 51, 84]. The possibility remains, however,
that binding of certain RNA targets might facilitate
PTB–PTB interactions.
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Figure 3. The structure of the free PTB. (a) Domain composition of PTB1. The gray, blue, green and red boxes indicate the location of the
RNA recognition motifs (RRMs), the RNP2 and RNP1 sequences, and the extended domain comprising the additional b5 strand,
respectively. The amino acid sequences of RNP1 and RNP2 of each RRM and of a consensus RRM (RRM-CS) are shown as well as the
amino acid sequences of the two other isoforms of PTB, PTB2 and PTB4. Structures of RRM1 [82] (b), RRM2 [82] (c), RRM4 [79, 80] (d)
and RRM3 [79, 80] (e) in their free form. The ribbons of the RRMs are shown in gray and the ribbons of the C-terminal extensions are
shown in red. Side-chains of important residues are shown in gray. ( f ) Stereoview of the interacting domains RRM3 andRRM4 in the free
form [80]. The ribbons of theRRMsare shown in gray and the ribbonsof theC-terminal extensions and the interdomain linker are shown in
red. Protein side-chains contributing to the interdomain interface are shown in blue (RRM3), green (RRM4) and black (linker),
respectively.
520 S. D. Auweter and F. H.-T. Allain Structure-function relationships of PTB
Hence, despite the discrepancy between consensus
RRMs and PTB RRMs in the primary sequence, the
structures of the RRMs of PTB revealed that residues
at equivalent positions within the RNP sequences
appeared to fulfill equivalent functions in RRM
folding and RNA binding. However, a few open
questions remained. How exactly do the b-sheets
recognize RNA in the absence of aromatic side chains
that serve as stacking partners, and how do the
additional b-strands of RRM2 and RRM3 assist in
RNA recognition? Does each RRM have a defined
sequence specificity? Will conformational changes
occur upon RNA binding?
The structure of PTB in complex with RNA and
proteins
To answer these questions, the NMR structures of all
four RRMs of PTB were solved in complex with short
pyrimidine tracts of the sequence 5’-CUCUCU-3’ [85]
(Fig. 4). This study could show that eachRRMof PTB
binds one RNA molecule of the sequence CUCUCU
and could confirm that all the RRMs bind pyrimidine
tracts with the help of their b-sheet [82, 86]. RRM1
(Fig. 4a) and RRM4 (Fig. 4c) recognize three nucleo-
tides (a UCU triplet), whereas RRM2 (Fig. 4b)
recognizes a CUNU sequence (N being any nucleo-
tide) and RRM3 (Fig. 4d) binds the quintet UCUCU.
Interestingly, in contrast to all other RRM-RNA
complexes solved to date [87], the third b-strand,
which contains the RNP1 residues, participates only
weakly in RNA binding. As there are no aromatic
residues at positions 3 and 5 of RNP1, hydrophobic
residues in b2 take over their function and stack with
the RNA bases [85]. The C-terminal extensions, i.e. ,
the additional b-strands, of RRM2 and RRM3 are
indeed involved in RNA recognition (Fig. 4b, d). In
the case of RRM2, one additional 3’U is bound, while
RRM3 uses the extension to contact the 3’CU
dinucleotide. In both cases, the linker between b4
and b5 makes most of these contacts [85]. A dense
network of hydrogen bonds connects moieties of the
protein backbone and side chains with the functional
groups of the bases. Hence, PTB is a sequence-specific
RNA binding protein with a different consensus
sequence recognized by each domain. While the
hydrogen bond network present in RRM1 predicts
that any YCU sequence can be bound, RRM2, RRM3
and RRM4 specifically recognize CU(N)N, YCUNN
and YCN, respectively [85] (where Y stands for
pyrimidine and N for any nucleotide). Finally, the
overall fold of the PTB RRMs is identical in free [79,
80, 82] and RNA-bound forms [85] (Figs. 3 and 4).
Solely some of the linkers appear to adopt a more
ordered structure in the presence of RNA, in partic-
ular the linkers connecting b4 and b5 of RRM2 and 3.
Interestingly, the structure of the RRM34 construct
hardly changes upon RNA binding (Fig. 4e). Because
of the unusual interaction betweenRRM3 andRRM4
that positions the two RNA binding surfaces away
from each other (Fig. 4e), RRM34 binds two short
pyrimidine tracts independently. Hence, NMR anal-
yses revealed that, while RRMs 1 and 2 of PTB
tumbled independently in solution, RRMs 3 and 4
form a single globular protein moiety, both in its free
and RNA-bound forms [85].
As mentioned above, for the splicing repression of
certain exons, PTB requires co-repressors like, for
example, Raver1. Interestingly, Rideau et al. [88]
could show by pulldown experiments and in vivo
fluorescence resonance energy transfer (FRET) that
several fragments of the Raver1 protein could bind to
PTB. Mutational analyses and NMR titration experi-
ments showed that a conserved sequence element ([S/
G]-[I/L]-L-G-X-X-P), which is present four times
within the Raver1 sequence, is responsible for the
interaction, and that the interaction is mediated by
RRM2 of PTB. The authors could furthermore show
that the interaction of the [S/G]-[I/L]-L-G-X-X-P
element with PTB is essential for Raver1-mediated
exon repression, but that additional elements, located
in the C terminus of the Raver1 protein, are required
for full repressor activity. NMR analyses with a
Raver1 PGVSLLGAPPKD peptide revealed that it
is the helical face of RRM2 that interacts with Raver1
(Fig. 4f) and that RRM2 can form a ternary complex
in which a pyrimidine tract is bound to the b-sheet
surface, while simultaneously the helical side serves as
an interaction platform for the Raver1 peptide motif
[88]. Thereby, the Raver1 motif binds in the shallow
groove formed by a1 and the a2b4 loop of PTB
RRM2, with the two leucines of the Raver1 peptide
engaged in hydrophobic contacts [88] (Fig. 4f).
How can the PTB structures explain its multiple
functions
The structural information gathered on the PTB
protein has disclosed several new aspects of its
function. The structures of the individual RRMs of
PTB in complex with RNA have revealed the number
and identity of the nucleotides bound by each RRM
and the minimum linker length (more than 10
nucleotides) between two pyrimidine-tracts in order
for both RRM3 and RRM4 to be bound to the RNA
[85] (Fig. 4). This allows a more meaningful interpre-
tation of experiments that aim at mapping PTB
binding sites within longer RNA molecules known
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to function through an interaction with PTB, and
might facilitate the identification of novel PTB
targets. For example, many studies identified PTB
binding sites by boundary analyses, gel shift experi-
ments and cross-linking [10, 15, 22, 32]. In light of the
complex structures [85], these findings can be more
easily interpreted. For example the minimum binding
sites for PTB RRM1–3 must contain at least 15
pyrimidines (considering the 12 nucleotides bound by
the three RRMs and the necessary allowed spacing
between eachRRMs). This now explains that only two
PTB binding sites, a high-affinity one spanning 20
nucleotides and a low affinity one spanning 12
nucleotides can be found on the 3’ splice-site of the
c-src N1 exon [10]. While all three RRMs are likely to
be accommodated on the 20-nucleotide site, only two
RRMs could bind on the remaining RNA, which will
lower the affinity for the second molecule.
Furthermore, in splicing regulation, it has been
previously proposed [2] and more recently shown
[15, 32] that PTB might function by displacing U2AF,
a factor essential for the initiation of a successful
splicing event, from the branch point pyrimidine tract.
U2AF has been shown to bind specifically to poly(U)
tracts [2, 89]. In contrast, the structures of the PTB
RRMs in complex with RNA show that PTB binds
preferentially to pyrimidine tracts containing cyto-
sines [85] (Fig. 4).Hence, the frequency of splicing of a
certain exon might be regulated in the cell by varying
the number of cytosines within the branch point
pyrimidine tract, making it a higher affinity target for
either of the two factors. Indeed, affinity measure-
ments [90] and molecular dynamics simulations [91]
could confirm thatRRMs 2 and 3 of PTBbind poly(U)
with significantly reduced affinity as compared to
poly(CU).
One of the most interesting features in terms of the
biological function of PTB that have been revealed
by structural analyses is the prominent inter-domain
contact between RRMs 3 and 4 [80, 85] (Figs. 3f and
4e). Several structures of two tandem RRMs bound
to RNA have been determined to date. In most of
these cases, as, for example, the poly(A) binding
protein (PABP) [92], sex-lethal [93] , or nucleolin
[94], both RRMs are separated by a small linker and
bind adjacent stretches within the same RNA mol-
ecule. This topology provides a single, large RNA
binding surface. In the case of PTB, however, the
Figure 4. The structure of PTB bound to RNA and Raver1. Structures of PTBRRM1 (a), RRM2 (b), RRM4 (c) and RRM3 (d) bound to
CUCUCURNA [85]. (e) Structure of RRM34 in complex with two pyrimidine tracts [85]. ( f ) Model of RRM2 bound to a peptide (P496-
D507) from Raver1 [88]. PTB side-chains involved in binding RNA are shown in black. RNA is shown in orange and Raver1 is shown in
green.
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relative orientation of tandem RRMs 3 and 4 makes
it impossible for the two domains to bind immedi-
ately adjacentRNA sequences [85] (Fig. 4e). Instead,
a linker of about 15 nucleotides between two
pyrimidine tracts is necessary if these pyrimidine
tracts are to be bound by both RRM3 and RRM4.
Hence, this topology provides an ideal scaffold to
induce RNA looping (Fig. 5). Therefore, the struc-
ture suggests that in contrast to the previous models
mentioned above, PTB multimerization is not re-
quired for loop induction. Rather, a single molecule
of PTB might fulfill this task with the help of its C-
terminal RRM3 and RRM4 (Fig. 5a, b). In line with
this model is the large body of evidence showing that
PTB is indeed a monomer in solution [10, 51, 84],
while previous measurements that found PTB is
dimeric were most likely complicated by the fact that
full-length PTB adopts an elongated shape, leading
to an apparent larger size in native gels and size-
exclusion columns, and by the fact that under non-
reducing conditions disulfide-mediated PTB dimers
could form [84]. In other words, with the help of
RRMs 3 and 4, PTB can bring pyrimidine tracts to
close proximity that may be fairly far apart within the
primary sequence of the RNA. This capacity might
also explain many of the other functions of PTB, like
its role in IRES-mediated translation initiation [43,
44, 46, 47] . The structure of the complex also explains
how several pyrimidine-rich pentaloops could create
a PTB binding site in an IRES [50] or the 3’UTR of
certain viral RNAs [95, 96] , since all four RRMs bind
only three to five pyrimidines each. However, it
remains to be determined which of the four RRMs
can bind such pentaloops (Fig. 2). Furthermore, the
unusual topology of RRM3 and 4 suggests that PTB,
by binding distant pyrimidine-tracts within the IRES,
could induce a dramatic conformational change in
the RNA, consistent with its role as an RNA
chaperone [51, 56, 97]. Indeed, RRM 3 and 4 of
PTB appear to be sufficient to stimulate the foot and
mouse disease virus (FMDV) IRES-driven trans-
lation [51]. Finally, the unique conformation of PTB
RRM34 explains how PTB might potentially bridge
3’ and 5’UTRs as observed in certain viral [98, 99] or
cellular [72] mRNAs. The RRM34 scaffold (Fig. 4e)
appears to be an ideal tool for this RNA remodeling
function.
It was demonstrated that more than one PTB mole-
cule is necessary for splicing regulation [10, 15] and
that PTB molecules cooperatively bind RNA [10, 15,
100]. How could this multimerization take place
without protein-protein interactions? In looping-out
RNA, PTB binding brings distant pyrimidine tracts in
close proximity, which could then favor binding of a
second molecule of PTB (Fig. 5c) that could then
favor binding of a third one, etc … In this context,
cooperative multimerization could be explained with-
out the need for any PTB-PTB interaction. Hence, the
mode of action of PTB as a splicing repressor could be
explained by its capacity for looping out RNA [7] or
Figure 5. Mechanisms of splic-
ing repression by PTB. (a) PTB
could repress splicing by looping
out either a branch-point ade-
nine [22] or (b) an alternative
exon [25, 104]. (c) Model of
cooperative binding around an
alternative exon that requires
binding of multiple PTB mole-
cules [10]. (d)Model of howPTB
and Raver1 can cooperate to
loop out and therefore repress
the splicing of an alternative
exon that is flanked by distant
intronic pyrimidine tracts [88].
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for multimerizing to create a zone of silencing [15] as
suggested previously [3] (Fig. 5).
The structural model of PTB RRM2 bound to the
Raver1 peptide (Fig. 4f) suggests several possible
modes of coordinated PTB and Raver1-mediated
splicing repression [88]. First of all, binding of Raver1
to the helical side of RRM2 might bring PTB and
Raver1 repressor domains in a correct relative ori-
entation so that they can act in concert to regulate
adjacent exons (Fig. 5d). These repressor domains
might include theRaver1C-terminus and the linkerC-
terminal to RRM2 of PTB, which have both been
shown to be important for the repressor function of
these proteins. Further evidence hinting at the func-
tional importance of the RRM2-RRM3 linker of PTB
includes the fact that it is alternatively spliced and that
it seems to be partially structured. Secondly, Raver1
and PTB could cooperate to recruit additional factors.
In particular, the C terminus of Raver1 contains
PXXP and PPLP motifs that are known to serve as
protein-protein interaction sites in other proteins. The
RRM2-RRM3 linker of PTB might fulfill a similar
role. Finally, as there are four PTBRRM2 recognition
motifs of sequence [S/G]-[I/L]-L-G-X-X-P present in
the Raver1 sequence, Raver1 might act as a bridging
molecule (Fig. 5d), mediating contacts between differ-
ent PTB molecules. In this context, it is interesting to
speculate that Raver1 might be required for splicing
repression in systems where upstream and down-
stream pyrimidine tracts recognized by PTB are quite
far apart in primary sequence and hence PTB requires
assistance for loop formation [88] (Fig. 5d). Indeed, in
the strongly Raver1-dependent a-tropomyosin exon
3, PTB binding elements around the exon are about
460 nucleotides apart, whereas in the Raver1-inde-
pendent c-src N1 exon, PTB binding sites are con-
tained within just about 120 nucleotides.
Conclusion and perspectives
A large body of high- and low-resolution structural
data on the PTB has been collected during the past
7 years. These studies have provided meaningful
insights into the function of this versatile and ubiq-
uitous protein. Recent studies have shown a role for
PTB in ovarian cancer, suggesting that PTB could be a
good potential therapeutic target [101]. These struc-
tures could, therefore, facilitate the design of a drug
against this cancer. However, many open questions
remain for future research.
First of all, it will be interesting to solve the structure
of the PTB paralog nPTB. There is accumulating
evidence that this protein, despite its high homology
to PTB, has distinct functional properties. For exam-
ple, splicing constructs, which appear to be solely
regulated by PTB, have been shown to be more
effectively spliced in neuronal cell extracts than in
HeLa or kidney cell extracts. Hence, neuronal nPTB
shows significantly reduced repressor function [9].
Furthermore, a recent micro-array study showed that
PTB and nPTB have a mutually exclusive expression
and regulate different sets of alternative exons during
neuron development [30]. It will bemost interesting to
see whether the functional differences between PTB
and nPTB are reflected in the nPTB structure.
Furthermore, all structural information has so far
been derived with very short single-stranded pyrimi-
dine oligonucleotides (Fig. 4). Recent convincing
studies have shown that pyrimidine tracts embedded
in the stem of a stem-loop are good binding sites for
PTB within IRESs [53] (Fig. 2d, e). The present
structure of PTB in complex with RNA [85] cannot
explain how PTB could recognize such RNA stem-
loops, suggesting that PTBmay bind theseRNAs via a
different mode of recognition and perhaps a different
RNA binding surface. Moreover, structural studies
using larger natural RNA targets would be crucial for
a more complete understanding of PTB function, in
particular a PTB-bound IRES RNA, where PTB
makes simultaneous contacts to both single-strand
and stem-loop RNA stretches (Fig. 2). These analyses
could reveal the detailed role of PTB as an RNA
remodeler of the IRESs [56].
Small angle X-ray scattering has revealed that the
linker between RRMs 2 and 3 is partially structured
[83]. Furthermore, there is evidence that this linker is
important for the repressor function of PTB, and the
fact that this linker is alternatively spliced is consistent
with an important role of this part of the protein for
PTB function. Therefore, it will be meaningful to
examine its functional role, as well as its structure, in
more detail and look for differences between the
splice variants.
Beside U2AF, the repressive role of PTB has been
antagonized bymany different RNAbinding proteins,
namely the CELF [13, 25] proteins ETR3 and CUG-
BP, RBM4 [33], TIA-1 [27, 34], Nova [40] and Fox-1
[102]. It will be valuable to gain a better understanding
of the molecular mechanisms behind these antago-
nisms.
Finally, it will be challenging to study the structures of
higher order complexes containing full-length PTB,
natural RNA targets and protein interaction partners.
These studies could provide insights into the func-
tional molecular machineries assembling on RNA
molecules within the cell.
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